HomeCompareGHMP vs ABBV

GHMP vs ABBV: Dividend Comparison 2026

GHMP yields 363636.36% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GHMP wins by $1.932717207947837e+32M in total portfolio value
10 years
GHMP
GHMP
● Live price
363636.36%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.932717207947837e+32M
Annual income
$193,167,223,774,015,200,000,000,000,000,000,000,000.00
Full GHMP calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GHMP vs ABBV

📍 GHMP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGHMPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GHMP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GHMP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GHMP
Annual income on $10K today (after 15% tax)
$30,909,090.91/yr
After 10yr DRIP, annual income (after tax)
$164,192,140,207,912,900,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GHMP beats the other by $164,192,140,207,912,900,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GHMP + ABBV for your $10,000?

GHMP: 50%ABBV: 50%
100% ABBV50/50100% GHMP
Portfolio after 10yr
$9.663586039739185e+31M
Annual income
$96,583,611,887,007,600,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GHMP
No analyst data
Altman Z
79.8
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GHMP buys
0
ABBV buys
0
No recent congressional trades found for GHMP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGHMPABBV
Forward yield363636.36%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1.932717207947837e+32M$102.3K
Annual income after 10y$193,167,223,774,015,200,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$1.9326488131115713e+32M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GHMP vs ABBV ($10,000, DRIP)

YearGHMP PortfolioGHMP Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$36,374,336$36,363,636.36$11,550$430.00+$36.36MGHMP
2$123,656,036,474$123,617,115,934.19$13,472$627.96+$123656.02MGHMP
3$392,881,298,290,830$392,748,986,331,802.80$15,906$926.08+$392881298.27MGHMP
4$1,166,631,909,043,447,800$1,166,211,526,054,276,600.00$19,071$1,382.55+$1166631909043.43MGHMP
5$3,237,677,014,801,259,000,000$3,236,428,718,658,582,000,000.00$23,302$2,095.81+$3237677014801259.00MGHMP
6$8,397,715,096,897,610,000,000,000$8,394,250,782,491,774,000,000,000.00$29,150$3,237.93+$8397715096897609728.00MGHMP
7$20,357,175,201,132,780,000,000,000,000$20,348,189,645,979,096,000,000,000,000.00$37,536$5,121.41+$2.035717520113278e+22MGHMP
8$46,121,511,639,300,970,000,000,000,000,000$46,099,729,461,835,750,000,000,000,000,000.00$50,079$8,338.38+$4.612151163930097e+25MGHMP
9$97,660,767,073,365,100,000,000,000,000,000,000$97,611,417,055,911,050,000,000,000,000,000,000.00$69,753$14,065.80+$9.76607670733651e+28MGHMP
10$193,271,720,794,783,700,000,000,000,000,000,000,000$193,167,223,774,015,200,000,000,000,000,000,000,000.00$102,337$24,771.77+$1.932717207947837e+32MGHMP

GHMP vs ABBV: Complete Analysis 2026

GHMPStock

Good Hemp, Inc. operates in the hemp and beverage industries in the United States. The company offers Good Hemp 2oh!, CANNA HEMP, and CANNA that are refreshing ready-to-drink waters in blueberry-blast, island coco-lime, kiwi-strawberry, lemon-twist, mango-fandango, and Q-cumbermint flavors; Good Hemp fizz, a line-up of carbonated refreshing ready-to-drink carbonated beverages in blueberry-bam, mango-tango, and citrus-twist flavors; Good Hemp Wellness, a line of CBD soft gels; and Diamond Creek High Alkaline Water, a 9.5pH high alkaline natural spring water. It distributes its products through direct store delivery and direct to retail channels, as well as direct to consumer through Amazon.com and Goodhemplivin.com. The company was formerly known as Lone Star Gold, Inc. and changed its name to Good Hemp, Inc. in September 2019. Good Hemp, Inc. was incorporated in 2007 and is based in Cornelius, North Carolina.

Full GHMP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GHMP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GHMP vs SCHDGHMP vs JEPIGHMP vs OGHMP vs KOGHMP vs MAINGHMP vs JNJGHMP vs MRKGHMP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.